Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-blind Placebo-controlled Study of CNP520 in Individuals at Risk for Alzheimer's Disease
jRCT2080223673Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of umibecestat in Alzheimer's disease (AD) (3 arms), sponsored by Novartis. Started Oct 2017; status: terminated.
02
Drugs
umibecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080223673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223673.